Eckert & Ziegler achieves best six-month result and raises profit forecast
This good six-month result is due to the solidification of increases in turnover and earnings in the core business which became visible in the first quarter. The core business contributed to a result of approximately EUR 0.40 per share in the second quarter. To this was added a significant contribution to earnings and liquidity in the Therapy segment from the Russian business, and this is expected to continue for the next few quarters. International Brachytherapy S.A. (IBt), an associated company of Eckert & Ziegler AG, had recently set up a joint venture with a Russian state fund corporation to manufacture prostate cancer implants in Russia and has now begun supplying plants and equipment. Developments in the largest business segment, Nuclear Medicine and Industry, were also encouraging. The six-month result after tax and minority interests was EUR 3.1 million, approximately 50% more than was earned in the same period last year (EUR 2.1 million). This means that Eckert & Ziegler Nuclitec GmbH was integrated into the Group more quickly and more cheaply than planned. Further improvements are expected in the second half of the year from gradual optimization taking place in procurement, logistics and sales. The Radiopharmaceuticals segment continues to make a profit despite high launch costs for new products.
The exact figures for the six-month period will be made public on August 4, 2009.